Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Subklewe

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Infection|October 1, 2025
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxisS Ehrlich, J Eufinger, N Tahiri, et al.
The Journal of Experimental Medicine|December 8, 1998
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cellsK Inaba, S Turley, F Yamaide, et al.
Leukemia|August 5, 2015
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanismC Krupka, P Kufer, R Kischel, et al.
Leukemia|September 13, 2017
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemiaK Reiter, H Polzer, C Krupka, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|October 18, 2014
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemiaN Sandhöfer, K H Metzeler, M Rothenberg, et al.
Leukemia|June 28, 2018
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLS Haubner, F Perna, T Köhnke, et al.
Leukemia|April 27, 2023
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AMLD Nixdorf, M Sponheimer, D Berghammer, et al.
Journal of Cancer Research and Clinical Oncology|July 25, 2023
Early clinical trial unit tumor board: a real-world experience in a national cancer networkL Weiss, K Dorman, M Boukovala, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Infection|October 1, 2025
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxisS Ehrlich, J Eufinger, N Tahiri, et al.
The Journal of Experimental Medicine|December 8, 1998
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cellsK Inaba, S Turley, F Yamaide, et al.
Leukemia|August 5, 2015
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanismC Krupka, P Kufer, R Kischel, et al.
Leukemia|September 13, 2017
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemiaK Reiter, H Polzer, C Krupka, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|October 18, 2014
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemiaN Sandhöfer, K H Metzeler, M Rothenberg, et al.
Leukemia|June 28, 2018
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLS Haubner, F Perna, T Köhnke, et al.
Leukemia|April 27, 2023
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AMLD Nixdorf, M Sponheimer, D Berghammer, et al.
Journal of Cancer Research and Clinical Oncology|July 25, 2023
Early clinical trial unit tumor board: a real-world experience in a national cancer networkL Weiss, K Dorman, M Boukovala, et al.
Pageof 3